NICE has joined a global group of organisations whose goal is to speed up the development and delivery of new, effective and affordable drugs to patients.

The New Drug Development Paradigms (NEWDIGS) program, led by the Center for Biomedical Innovation (CBI) at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts brings together pharmaceutical companies, academic researchers, patient advocacy groups, government agencies involved in healthcare and other experts to collaborate on ways to reliably and sustainably deliver new, better, affordable therapeutics to the right patients faster.

“Through NEWDIGS we’ll work with others to explore how our guidance development processes can contribute to faster and better drug development and delivery,” said Professor Sarah Garner, NICE’s associate director for R&D. “The initiative uses the principles of systems engineering – something MIT is famous for – to design and test scenarios for the development of new drugs.”

The field of systems engineering is interested in the design and management of complex projects, ranging from bridge building to spacecraft design. Systems engineers use a variety of different tools, including modelling and simulation, to redesign work processes. Knowledge from different branches of engineering and science is used to introduce technological innovations into the planning and development stages of a system – in this case drug development.

For more details, go to: https://www.nice.org.uk/news/article/nice-joins-global-group-to-accelerate-access-to-new-drugs